Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of small-molecule cyclin D1-ablative agents.

Jui-Wen Huang1, Chung-Wai Shiau, Jian Yang

  • 1Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, 336 Parks Hall, The Ohio State University, 500 West 12th Avenue, Columbus, Ohio 43210, USA.

Journal of Medicinal Chemistry
|July 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the stomach: Repurposing bismuth tripotassium dicitrate as a novel strategy against multidrug-resistant Mycobacterium abscessus.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi·2026
Same author

<i>Letter:</i> Involuntary Starvation for a Good Death: A Position Statement from the Taiwan Academy of Hospice Palliative Medicine.

Journal of palliative medicine·2026
Same author

External validation of the R-EDByUS score for neuroprognostication in out-of-hospital cardiac arrest.

Resuscitation plus·2026
Same author

Discovery of an N,N'-diarylurea with potent activity against multidrug-resistant Staphylococcus aureus via perturbation of membrane homeostasis.

European journal of medicinal chemistry·2026
Same author

External validation of MIRACLE2, rCAST, and TTM scores for neurological outcomes in comatose out-of-hospital cardiac arrest survivors: A multi-center study.

Heart & lung : the journal of critical care·2026
Same author

Early hypoxia prediction in diseased patients via wheezing sounds in respiration: a prospective cohort study.

Frontiers in medicine·2026

A novel compound, STG28, effectively reduces cyclin D1 levels in breast cancer cells. This targeted approach inhibits cancer cell proliferation and may offer new therapeutic strategies for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Cyclin D1 is a key regulator of cell cycle progression.
  • Overexpression of cyclin D1 is implicated in tumorigenesis and drug resistance.
  • Previous studies identified troglitazone's ability to repress cyclin D1 via a PPARgamma-independent pathway.

Purpose of the Study:

  • To develop novel cyclin D1-ablative agents.
  • To investigate the therapeutic potential of STG28, a structural analog of troglitazone.
  • To evaluate STG28's mechanism of action and specificity in breast cancer cells.

Main Methods:

  • Synthesis and structural optimization of troglitazone analogs.
  • Assessment of cyclin D1 repression and proteasomal degradation.

Related Experiment Videos

  • Evaluation of cell proliferation inhibition in MCF-7 breast cancer cells.
  • Analysis of STG28's specificity on other cyclins and CDK-dependent kinases.

    • Main Results:

    • STG28, derived from Delta2TG, effectively ablates cyclin D1 at low micromolar concentrations.
    • STG28 induces proteasomal degradation of cyclin D1 with high specificity.
    • STG28 inhibits MCF-7 cell proliferation.
    • STG28 does not significantly alter the expression of other cyclins or CDKs.

    Conclusions:

    • STG28 is a potent and specific cyclin D1-ablating agent.
    • The PPARgamma-independent mechanism of cyclin D1 repression is maintained in STG28.
    • STG28 demonstrates therapeutic relevance as a potential anti-cancer agent targeting cyclin D1.